Synergistic effect of probiotics, butyrate and l-Carnitine in treatment of IBD

Journal of Medical Hypotheses and Ideas

Volumn 7, Issue 2, 2013, Pages 50-53

  Moeinian, Mahsa ^a   Farnaz Ghasemi Niri, Seyedeh ^a   Mozaffari, Shilan ^a   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Butyrate; Inflammatory bowel disease; I B kinase; L Carnitine; Oxidative stress; Probiotics

Indexed keywords

ADAPTOR PROTEIN; BUTYRIC ACID; CARNITINE; CARNITINE TRANSPORTER 2; CATALASE; GLUTATHIONE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; MONOCARBOXYLATE TRANSPORTER 1; MYELOPEROXIDASE; PROBIOTIC AGENT; REACTIVE OXYGEN METABOLITE; RIBOSOME INACTIVATING PROTEIN; SILENCER OF DEATH DOMAIN PROTEIN; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIFIDOBACTERIUM BIFIDUM; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; INFLAMMATORY BOWEL DISEASE; LACTOBACILLUS CASEI; LIPID PEROXIDATION; NONHUMAN; OCTN2 GENE; OXIDATIVE STRESS; SACCHAROMYCES BOULARDII; SIGNAL TRANSDUCTION; SMCT1 GENE; UPREGULATION;

EID: 84906791988     PISSN: 22517294     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmhi.2013.02.003     Document Type: Article

References (38)

1. Sartor R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006, 3(7):390-407.
2. Oz H.S., Ebersole J.L. Application of prodrugs to inflammatory diseases of the gut. Molecules 2008, 13(2):452-474.
3. Rezaie A., Parker R.D., Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause?. Dig Dis Sci 2007, 52:2015-2021.
4. Mozaffari S., Abdollahi M. Melatonin, a promising supplement in inflammatory bowel disease: a comprehensive review of evidences. Curr Pharm Des 2011, 17(38):4372-4378.
5. Nikfar S., Rahimi R., Rezaie A., Abdollahi M. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci 2009, 54:1157-1170.
6. Nikfar S., Mirfazaelian H., Abdollahi M. Efficacy and tolerability of immunoregulators and antibiotics in fistulizing Crohn's disease: a systematic review and meta-analysis of placebo-controlled trials. Curr Pharm Des 2010, 16(33):3684-3698.
7. Hadjibabaie M., Rastkari N., Rezaie A., Abdollahi M. The adverse drug reaction in the gastrointestinal tract: an overview. Int J Pharmacol 2005, 1(1):1-8.
8. Rahimi R., Shams-Ardekani M.R., Abdollahi M. A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease. World J Gastroenterol 2010, 16(36):4504-4514.
9. Rahimi R., Mozaffari S., Abdollahi M. On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies. Dig Dis Sci 2009, 54(3):471-480.
10. Nikfar S., Rahimi R., Rahimi F., Derakhshani S., Abdollahi M. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 2008, 51(12):1775-1780.
11. Salari P., Nikfar S., Abdollahi M. A meta-analysis and systematic review on the effect of probiotics in acute diarrhea. Inflamm Allergy Drug Targets 2012, 11:3-14.
12. Rahimi R., Nikfar S., Rezaie A., Abdollahi M. A meta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: evidence for prevention of disease relapse and maintenance of remission. Arch Med Sci 2008, 4(2):185-190.
13. Rahimi R., Nikfar S., Rahimi F., Elahi B., Derakhshani S., Vafaie M., et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 2008, 53(9):2524-2531.
14. Segain J.P., Raingeard de la Blétière D., Bourreille A., Leray V., Gervois N., Rosales C., et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000, 47(3):397-403.
15. Fortin G., Yurchenko K., Collette C., Rubio M., Villani A.C., Bitton A., et al. l-carnitine, a diet component and organic cation transporter OCTN ligand, displays immunosuppressive properties and abrogates intestinal inflammation. Clin Exp Immunol 2009, 156(1):161-171.
16. Hegazy S.K., El-Bedewy M.M. Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J Gastroenterol 2010, 16(33):4145-4151.
17. Esmaily H., Vaziri-Bami A., Miroliaee A.E., Baeeri M., Abdollahi M. The correlation between NF-κB inhibition and disease activity by coadministration of silibinin and ursodeoxycholic acid in experimental colitis. Fundam Clin Pharmacol 2011, 25(6):723-733.
18. Howarth G.S. Inflammatory bowel disease, a dysregulated host-microbiota interaction: are probiotics a new therapeutic option?. J Gastroenterol Hepatol 2008, 23(12):1777-1779.
19. Gloire G., Legrand-Poels S., Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 2006, 72(11):1493-1505.
20. Koc A., Ozkan T., Karabay A.Z., Sunguroglu A., Aktan F. Effect of l-carnitine on the synthesis of nitric oxide in RAW 264·7 murine macrophage cell line. Cell Biochem Funct 2011, 29(8):679-685.
21. Carroll I.M., Andrus J.M., Bruno-Bárcena J.M., Klaenhammer T.R., Hassan H.M., Threadgill D.S. Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis. Am J Physiol Gastrointest Liver Physiol 2007, 293(4):G729-G738.
22. Lin P.W., Myers L.E., Ray L., Song S.C., Nasr T.R., Berardinelli A.J., et al. Lactobacillus rhamnosus blocks inflammatory signaling in vivo via reactive oxygen species generation. Free Radic Biol Med 2009, 47(8):1205-1211.
23. Kurutas E.B., Cetinkaya A., Bulbuloglu E., Kantarceken B. Effects of antioxidant therapy on leukocyte myeloperoxidase and Cu/Zn-superoxide dismutase and plasma malondialdehyde levels in experimental colitis. Mediators Inflamm 2005, 2005(6):390-394.
24. Bradley J.R. TNF-mediated inflammatory disease. J Pathol 2008, 214(2):149-160.
25. LeBlanc J.G., del Carmen S., Miyoshi A., Azevedo V., Sesma F., Langella P., et al. Use of superoxide dismutase and catalase producing lactic acid bacteria in TNBS induced Crohn's disease in mice. J Biotechnol 2011, 151(3):287-293.
26. Cetinkaya A., Bulbuloglu E., Kantarceken B., Ciralik H., Kurutas E.B., Buyukbese M.A. Effects of l-carnitine on oxidant/antioxidant status in acetic acid-induced colitis. Dig Dis Sci 2006, 51(3):488-494.
27. Boirivant M., Strober W. The mechanism of action of probiotics. Curr Opin Gastroenterol 2007, 23(6):679-692.
28. Russo I., Luciani A., De Cicco P., Troncone E., Ciacci C. Butyrate attenuates lipopolysaccharide-induced inflammation in intestinal cells and Crohn's mucosa through modulation of antioxidant defense machinery. PLoS One 2012, 7(3):e32841.
29. Sakon S., Xue X., Takekawa M., Sasazuki T., Okazaki T., Kojima Y., et al. NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J 2003, 22(15):3898-3909.
30. Butzner J.D., Parmar R., Bell C.J., Dalal V. Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat. Gut 1996, 38(4):568-573.
31. Ghasemi-Niri S.F., Solki S., Didari T., Mozaffari S., Baeeri M., Rezvanfar M.A., et al. Better efficacy of Lactobacillus casei in combination with Bifidobacterium bifidum or Saccharomyces boulardii in recovery of inflammatory markers of colitis in rat. Asian J Anim Vet Adv 2012, 7(11):1148-1156.
32. Ghasemi-Niri S.F., Abdolghaffari A.H., Fallah-Benakohal S., Hosseinpour-Feizi M., Mahdaviani P., Jamalifar H., et al. On the benefit of whey-cultured Lactobacillus casei in murine colitis. J Physiol Pharmacol 2011, 62(3):341-346.
33. Chuang L., Wu K.G., Pai C., Hsieh P.S., Tsai J.J., Yen J.H., et al. Heat-killed cells of lactobacilli skew the immune response toward T helper 1 polarization in mouse splenocytes and dendritic cell-treated T cells. J Agric Food Chem 2007, 55(26):11080-11086.
34. Delcenserie V., Martel D., Lamoureux M., Amiot J., Boutin Y., Roy D. Immunomodulatory effects of probiotics in the intestinal tract. Curr Issues Mol Biol 2008, 10(1-2):37-54.
35. Nikfar S., Darvish-Damavandi M., Abdollahi M. A review and meta-analysis of the efficacy of antibiotics and probiotics in management of pouchitis. Int J Pharmacol 2010, 6(6):826-835.
36. Elahi B., Nikfar S., Derakhshani S., Vafaie M., Abdollahi M. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci 2007, 53:1278-1284.
37. Frenkel K. Carcinogen-mediated oxidant formation and oxidative DNA damage. Pharmacol Ther 1992, 53(1):127-166.
38. Wang C., Sadovova N., Ali H.K., Duhart H.M., Fu X., Zou X., et al. L-carnitimirfazan protects neurons from1-methyl-4-phenylpyridinium-induced neuronal apoptosis in rat forebrain culture. Neuroscience 2007, 144(1):46-55.